Loading
companiesCompany
Multitude Therapeutics
Multitude Therapeutics is a China-based biotechnology company running 4 late-stage cancer trials of AMT-116, AMT-676 and AMT-253 in colorectal cancer, melanoma and non-small-cell lung cancer.
Also called: Multitude Therapeutics Inc.
Overview
Multitude Therapeutics, based in Shanghai, China, is a biotechnology company. Multitude Therapeutics is a clinical-stage biotechnology company in China developing antibody-drug conjugate therapies for cancer, using its PAD molecular design platform and MabArray target discovery platform. On ClinicalTrials.gov it is the lead sponsor of 4 recruiting or active phase 2 and phase 3 interventional cancer trials, testing AMT-116, AMT-676, AMT-253 and AK112 in colorectal cancer, melanoma and non-small-cell lung cancer. The largest, NCT07474727 (A Phase II Study of AMT-676 Combination Therapies in Advanced Colorectal Cancer), plans to enrol 180 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.
Headquarters
Shanghai, CN
Scorecard
All companies#445of 1244 companies, score 7
- phase 1/2 +1
- modalities +2
- registry trials +4
0 approved, 0 in phase 3, 1 earlier, 0 targets, 4 registry studies. Formula on the scorecards page.
Type
Stage
Growth stage
Phase 2Antibody-drug conjugate
AMT-116 is an antibody-drug conjugate from Multitude Therapeutics Inc., in registered phase 2 trials for non-small-cell lung cancer, small-cell lung cancer.
cancers
drugs
Phase 2Antibody-drug conjugate
trials
A Phase II Study of AMT-676 Combination Therapies in Advanced Colorectal CancerAMT-116 in Combination With AK112 in Patients With Lung CancerAMT-116 in Patients with Solid TumorsAMT-253 in Patients With Advanced Solid TumoursGlobal, Multicenter Study of AMT-116 Versus Investigator's Choice in Participants With Advanced or Metastatic Non-squamous EGFR-Wildtype Non-Small Cell Lung Can